JAK2 and neoplasm: The Janus kinase (JAK) inhibitors could inhibit tumor growth in gastric and colorectal cancer via suppressing the IL-6/JAK2/signal transducer and activator of transcription 3 (STAT3) pathway and enhancing the secretion of anti-tumor cytokines.